The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes
Open accessAbstract
Human rhinoviruses, the most important etiologic agents of the common cold, are messenger-active single-stranded monocistronic RNA viruses that have evolved a highly complex cascade of proteolytic processing events to control viral gene expression and replication. Most maturation cleavages within the precursor polyprotein are mediated by rhinovirus 3C protease (or its immediate precursor, 3CD), a cysteine protease with a trypsin-like polypeptide fold. High-resolution crystal structures of the enzyme from three viral serotypes have been used for the design and elaboration of 3C protease inhibitors representing different structural and chemical classes. Inhibitors having α,β-unsaturated carbonyl groups combined with peptidyl-binding elements specific for 3C protease undergo a Michael reaction mediated by nucleophilic addition of the enzyme’s catalytic Cys-147, resulting in covalent-bond formation and irreversible inactivation of the viral protease. Direct inhibition of 3C proteolytic activity in virally infected cells treated with these compounds can be inferred from dose-dependent accumulations of viral precursor polyproteins as determined by SDS/PAGE analysis of radiolabeled proteins. Cocrystal-structure-assisted optimization of 3C-protease-directed Michael acceptors has yielded molecules having extremely rapid in vitro inactivation of the viral protease, potent antiviral activity against multiple rhinovirus serotypes and low cellular toxicity. Recently, one compound in this series, AG7088, has entered clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weakly Polar Interactions In Proteins
Burley, S. K., & Petsko, G. A. (1988) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60376-9 · Cited by 729
Poliovirus RNA synthesis utilizes an RNP complex formed around the 5′-end of viral RNA.
Andino, R., Rieckhof, G. E., Achacoso, P. L., & Baltimore, D. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06032.x · Cited by 494
Kräusslich, H.-G., & Wimmer, E. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.003413 · Cited by 450
Matthews, D. A., Smith, W. W., Ferre, R. A., Condon, B., Budahazi, G., Slsson, W., Villafranca, J. E., Janson, C. A., McElroy, H. E., Gribskov, C. L., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90059-0 · Cited by 356
Self-citationPicornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases
Allaire, M., Chernaia, M. M., Malcolm, B. A., & James, M. N. G. (1994) · Nature · doi:10.1038/369072a0 · Cited by 306
The major and minor group receptor families contain all but one human rhinovirus serotype
Uncapher, C. R., Dewitt, C. M., & Colonno, R. J. (1991) · Virology · doi:10.1016/0042-6822(91)90098-v · Cited by 239
In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease
Patick, A. K., Binford, S. L., Brothers, M. A., Jackson, R. L., Ford, C. E., Diem, M. D., Maldonado, F., Dragovich, P. S., Zhou, R., Prins, T. J., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.10.2444 · Cited by 221
Self-citationRefined X-ray crystallographic structure of the poliovirus 3C gene product 1 1Edited By D. Rees
Mosimann, S. C., Cherney, M. M., Sia, S., Plotch, S., & James, M. N. G. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1306 · Cited by 200
Xiang, W., Harris, K. S., Alexander, L., & Wimmer, E. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3658-3667.1995 · Cited by 197
Dragovich, P. S., Prins, T. J., Zhou, R., Webber, S. E., Marakovits, J. T., Fuhrman, S. A., Patick, A. K., Matthews, D. A., Lee, C. A., Ford, C. E., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9805384 · Cited by 180
Self-citationDesign, Synthesis, and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3C Protease
Webber, S. E., Tikhe, J. G., Worland, S. T., Fuhrman, S. A., Hendrickson, T. F., Matthews, D. A., Love, R. A., Patick, A. K., Meador, J. W., Ferre, R. A., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960603e · Cited by 159
Self-citationViral proteinases: weakness in strength
Kay, J., & Dunn, B. M. (1990) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(90)90015-t · Cited by 118
Dragovich, P. S., Webber, S. E., Babine, R. E., Fuhrman, S. A., Patick, A. K., Matthews, D. A., Reich, S., Marakovits, J. T., Prins, T. J., Zhou, R., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9800696 · Cited by 112
Self-citationStructure-activity relationships for inhibition of papain by peptide Michael acceptors
Liu, S., & Hanzlik, R. P. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00084a012 · Cited by 109
Dragovich, P. S., Webber, S. E., Babine, R. E., Fuhrman, S. A., Patick, A. K., Matthews, D. A., Lee, C. A., Reich, S., Prins, T. J., Marakovits, J. T., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980068d · Cited by 92
Self-citationWebber, S. E., Okano, K., Little, T. L., Reich, S., Xin, Y., Fuhrman, S. A., Matthews, D. A., Love, R. A., Hendrickson, T. F., Patick, A. K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980071x · Cited by 89
Self-citationPicornavirus Protein Processing—Enzymes, Substrates, and Genetic Regulation
Lawson, M. A., & Semler, B. L. (1990) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-75602-3_3 · Cited by 83
Chemotherapy of rhinovirus colds
Sperber, S. J., & Hayden, F. G. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.4.409 · Cited by 79
Vinylogous amino acid esters: a new class of inactivators for thiol proteases
Hanzlik, R. P., & Thompson, S. A. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00372a001 · Cited by 72
Dragovich, P. S., Prins, T. J., Zhou, R., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980537b · Cited by 68
Self-citationDragovich, P. S. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00005-x · Cited by 43
Self-citationMeara, J. P., & Rich, D. H. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00396-b · Cited by 10
Cited by
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Protease Inhibitors: Current Status and Future Prospects
Leung, D., Abbenante, G., & Fairlie, D. P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990412m · Cited by 883
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030324 · Cited by 727
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660
Metadata
- Authors
- Matthews, D. A., Dragovich, P. S., Webber, S. E., Fuhrman, S. A., Patick, A. K., Zalman, L. S., Hendrickson, T. F., Love, R. A., Prins, T. J., Marakovits, J. T., Zhou, R., Tikhe, J., Ford, C. E., Meador, J. W., Ferre, R. A., Brown, E. L., Binford, S. L., Brothers, M. A., DeLisle, D. M., & Worland, S. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-09-28
- Volume
- 96
- Issue
- 20
- Pages
- 11000-11007
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2120348672
- Cited by
- 318
- References
- 22
- FWCI
- 10.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.